Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy

被引:1
|
作者
Zhang, Yuanyuan [1 ,2 ]
Yang, Jingjing [3 ]
Li, Jianzhong [1 ]
Sun, Jiani [1 ]
Zhou, Ling [1 ]
Xu, Deyu [1 ]
Sha, Wengang [1 ]
Dai, Lan [4 ]
Shen, Lei [1 ]
机构
[1] Soochow Univ, Dept Nephrol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Nanjing Univ, Suzhou Hosp, Affiliated Hosp, Dept Nephrol,Med Sch, Suzhou, Peoples R China
[3] BenQ Med Ctr, Dept Nephrol, Suzhou, Peoples R China
[4] Soochow Univ, Jiangsu Inst Hematol, Minist Hlth, Key Lab Thrombosis & Hemostasis,Affiliated Hosp 1, Suzhou, Peoples R China
关键词
Rituximab; Primary membranous nephropathy; T lymphocyte subsets; B lymphocyte cells; Anti-PLA2R antibody; RECEPTOR; CHILDREN; CELLS;
D O I
10.1186/s12882-024-03521-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe aim of this study was to investigate the effects and significance of rituximab (RTX) on the levels of T lymphocyte subsets in patients diagnosed with primary membranous nephropathy (PMN).MethodsA total of 58 PMN patients and 25 healthy donors were chosen as the subjects. Among the PMN patients, 40 individuals received RTX treatment and completed at least 6 months of follow-up. All subjects underwent flow cytometry analysis to determine the peripheral blood lymphocyte subsets. The changes in anti-PLA2R antibody titers and 24-hour urinary protein levels were evaluated by ELISA and Biuret method before and after treatment.Results(1) The PMN group exhibited a significantly greater percentage of peripheral blood CD3-CD19+ B cells than the healthy group, which is consistent with the findings of previous reports. Additionally, compared with those in the peripheral blood of healthy individuals, the numbers of CD4+ central memory T cells, CD4+ effector memory T cells, CD4+/CD8+, and CD4+CD25+ T cells in the PMN peripheral blood were markedly greater. However, the number of peripheral blood Treg cells was reduced in the PMN group. (2) After 6 months of RTX treatment, PMN patients exhibited significant decreases in anti-PLA2R antibody titers, 24-hour urinary protein levels, and peripheral blood CD3-CD19+ B cells. Importantly, RTX administration decreased CD4+CD25+ T cells and CD4+/CD8+ in the peripheral blood of PMN patients and improved Treg cell levels. (3) RTX treatment induced alterations in the CD4+ T lymphocyte subsets in PMN patients, which did not correlate with B lymphocyte counts or anti-PLA2R antibody titers.ConclusionsRTX treatment might have a beneficial impact on cellular immunity by effectively restoring the balance of CD4+ T lymphocyte subsets in PMN patients, which is beyond its effects on B cells and antibody production.Trial registrationThe research was registered at the First Affiliated Hospital of Soochow University. Registration Number: MR-32-23-016211. Registration Date: May 31, 2023.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy
    Yuanyuan Zhang
    Jingjing Yang
    Jianzhong Li
    Jiani Sun
    Ling Zhou
    Deyu Xu
    Wengang Sha
    Lan Dai
    Lei Shen
    BMC Nephrology, 25
  • [2] Rituximab bioavailability in primary membranous nephropathy
    Boyer-Suavet, Sonia
    Andreani, Marine
    Cremoni, Marion
    Brglez, Vesna
    Benzaken, Sylvia
    Bernard, Ghislaine
    Nachman, Patrick
    Esnault, Vincent
    Seitz-Polski, Barbara
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (08) : 1423 - 1425
  • [3] Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
    Teisseyre, Maxime
    Cremoni, Marion
    Boyer-Suavet, Sonia
    Ruetsch, Caroline
    Graca, Daisy
    Esnault, Vincent L. M.
    Brglez, Vesna
    Seitz-Polski, Barbara
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] Rituximab in Primary Membranous Nephropathy With Severe CKD
    Naik, Sachin
    Shukla, Shubham
    Kumar, Vinod
    Sain, Thakur
    Sekar, Aravind
    Pal, Deeksha
    Kumar, Ashwini
    Minz, Ranjana
    Rathi, Manish
    Nada, Ritambhra
    Kohli, Harbir Singh
    Ramachandran, Raja
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (06): : 1270 - 1271
  • [5] EFFICACY OF RITUXIMAB IN A CASE OF PRIMARY MEMBRANOUS NEPHROPATHY
    Printza, Nikoleta
    Stabouli, Stella
    Dotis, John
    Georeli, Ireni
    Maliahova, Olga
    Sidira, Christina
    Papachristou, Fotios
    PEDIATRIC NEPHROLOGY, 2017, 32 (09) : 1777 - 1777
  • [6] Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
    Gao, Shuang
    Cui, Zhao
    Wang, Xin
    Zhang, Yi-miao
    Wang, Fang
    Cheng, Xu-yang
    Meng, Li-qiang
    Zhou, Fu-de
    Liu, Gang
    Zhao, Ming-hui
    FRONTIERS IN MEDICINE, 2021, 8
  • [7] Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy
    Hu, Xiaofan
    Zhang, Muyin
    Xu, Jing
    Gao, Chenni
    Yu, Xialian
    Li, Xiao
    Ren, Hong
    Wang, Weiming
    Xie, Jingyuan
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (12): : 1594 - 1602
  • [8] Optimization of rituximab therapy in primary membranous nephropathy with artificial intelligence
    Destere, A.
    Teyssiere, M.
    Merino, D.
    Cremoni, M.
    Benito, S.
    Gerard, A.
    Drici, M. D.
    Seitz-Polski, B.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 74 - 75
  • [9] Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
    Naik, Sachin
    Pal, Deeksha
    Shukla, Shubham
    Kumar, Vinod
    Kumar, Ashwini
    Jha, Vivekanand
    Minz, Ranjana
    Sethi, Jasmine
    Bharati, Joyita
    Divyaveer, Smita
    Kumar, Vivek
    Rathi, Manish
    Kohli, Harbir Singh
    Ramachandran, Raja
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (08): : 1660 - 1664
  • [10] EFFECT OF RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEMBRANOUS NEPHROPATHY
    Akyildiz, Arif
    Uludag, Omer
    Mirioglu, Safak
    Ucar, Ali Riza
    Demir, Erol
    Caliskan, Yasar Kerem
    Ozluk, Yasemin
    Turkmen, Aydin
    Sever, Mehmet Sukru
    Yazici, Halil
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 657 - 657